New pill aims to ease burning nerve pain in diabetes
NCT ID NCT07159243
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tests an experimental oral drug called HL-1186 for diabetic peripheral neuropathic pain—a common, painful nerve condition caused by diabetes. About 180 adults with type 1 or type 2 diabetes will receive either HL-1186 or a placebo for 12 weeks. The main goal is to see if the drug reduces daily pain scores more than placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HL-1186 tablet
What this could lead to
If it works, this could lead to a new oral medication to reduce nerve pain in people with diabetes.
What could go wrong
This is an early Phase 2 trial with only 180 participants, so results may not apply to everyone. The drug may not prove better than a placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC PERIPHERAL NEUROPATHIC PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••